Dr Reddy’s

Buy Dr Reddy's Laboratories With Target Of Rs 1572

Dr Reddy's Laboratories LtdDRL’s Q4FY11 results were ahead of estimates driven by generic Allegra D-24 and the PSAI segment. We expect generic Allegra D-24 to have contributed USD25mn (product now moved to OTC). DRL indicated that the lower growth in India was on back of price cuts in the market which provides an early signal to rising competition. Further the recurring EBIT margins were bit under pressure on back of higher SG&A and R&D cost. We continue to maintain HOLD rating with a revised TP of Rs1,572 valuing the base business at Rs1,501 (20x June’12 recurring earnings) and Rs71/share for P-IV/ limited competition opportunities.

Short Term Buy Call For Dr Reddy's

Short Term Buy Call For Dr Reddy'sTechnical analyst Brijesh Singh of India Advantage has maintained 'buy' rating on Dr Reddy's Laboratories Limited stock with a short term target of Rs 1730.

According to analyst, the investors can buy the stock with a stop loss of Rs 1660

The stock of the company, on April 20, closed at Rs 1632.45 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 47.97 and 34.71 respectively.

The share price has seen a 52-week high of Rs 1855 and a low of Rs 1161 on BSE.

Dr Reddy's Intraday Buy Call

Dr Reddy's Intraday Buy CallTechnical analyst Simi Bhaumik has maintained 'hold' rating on Dr Reddy`S Laboratories Limited stock with an intra-day target of Rs 1666.

According to analyst, the investors can buy the stock with stop loss of Rs 1618.

The stock of the company, on April 13, closed at Rs 1632.45 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 47.97 and 34.29 respectively.

The share price has seen a 52-week high of Rs 1855 and a low of Rs 1161.10 on BSE.

Long Term Buy Call For Dr Reddy's

Long Term Buy Call For Dr Reddy'sTechnical analyst Hitesh Chotalia maintained 'hold' rating on Jet Airways Limited stock to attain a target of Rs 1728.

According to analyst, the investors can buy the stock with a stop loss of Rs 1570.

Today, the stock of the company opened at Rs 1619 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1855 and a low of Rs 1092.25 on BSE.

Current EPS & P/E ratio stood at 47.97 and 33.36 respectively.

Dr Reddy's Laboratories recorded a consolidated net profit of Rs 273.14 crore for October-December period.

Hold Dr Reddy'd Stock With Target Price Of Rs 1,584

Hold Dr Reddy'd Stock With Target Price Of Rs 1,584DRL’s Q3FY11 results were a mixed bag. The sales growth and adjusted margins were tad below expectation but adjusted PAT was above our estimates on back of lower tax rate. Near term trigger for the stock would be launches of Fondaparinux and generic Allegra D-24 products in US.

DRL posts steady profit increase in Q1

DRL posts steady profit increase in Q1India's second largest drug company, Dr. Reddy's Laboratories (DRL) has said that it has seen a steady growth in profit which grew by 7.5 per cent during the first quarter ending June 30. In money terms it meant that profit has gone up from Rs227 crore to Rs. 244 crore as compared to the last year. This was said in filing submitted to the National Stock Exchange.

Dr Reddy’s consolidated net slithered

Dr Reddy’s consolidated net slitheredDr Reddy’s Laboratories has recorded a 14.28% turn down in its combined net profit by Rs 209.55 crore from Rs 244.47 crore for its first quarter ending in June 30, 2010, at the constant period in the previous fiscal.

Net income arriving out from sales and services stands at Rs 1,683.13 crore, contrasted with Rs 1,818.94 crore in the similar period of the consequent fiscal. With a plummet in profits, its return per share dwindled down by Rs 12.41 from Rs 14.51 in the previous period.

Short Term Buy Call For Dr Reddy's

Short Term Buy Call For Dr Reddy'sStock market analyst Sudarshan Sukhani has maintained 'buy' rating on Dr Reddy's Laboratories Ltd stock with short term target of Rs 1500.

According to analyst, the investors can buy the stock stop loss of Rs 1455.

Today, the stock of the company opened at Rs 1467.15 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 47.96 and 30.66 respectively.

The share price has seen a 52-week high of Rs 1515 and a low of Rs 750.50 on BSE.

Dr Reddys Laboratories, on June 29, introduced Anastrozole tabs (1mg) in the United States.

Buy Dr Reddy’s With Stop Loss Of Rs 1400

Buy Dr Reddy’s With Stop Loss Of Rs 1400Stock market analyst Anil Singhvi has maintained 'buy' rating on Dr Reddy`S Laboratories Ltd stock with target of Rs 1450.

According to Singhvi, the investors can buy the stock with stop loss of Rs 1400.

The stock of the company, on June 16, closed at Rs 1414 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1515 and a low of Rs 715 on BSE.

Current EPS & P/E ratio stood at 47.96 and 29.57 respectively.

U.S. court refrains Dr Reddy’s from launching Allegra

U.S. court refrains Dr Reddy’s from launching AllegraIt seems that there is no end of trouble for Dr Reddy's Laboratories in the US markets. A court in the US has refrained Dr Reddy's Laboratories from launching its Allegra. This has been a major setback to the leading Pharmaceutical Company of the country.

The US court has passed an injunction order against the India Pharmaceutical major.

Dr Reddys Laboratories eyeing on 20% growth next year

Dr Reddys Laboratories eyeing on 20% growth next yearDr Reddys Laboratories has announced its fourth quarter financial results for the fiscal year 2009-10 and has managed to post a significant net profit and revenue. The firm has posted a net profit of Rs 253 crore for the quarter that ended in 31st March, 2010. This net profit figure was at Rs 156 crore for the same quarter in the preceding year.

Anti-allergic drug Allegra gets nod from US FDA

Anti-allergic drug Allegra gets nod from US FDADr Reddy's Laboratories is rejoicing at the moment, owing to the fact that it has finally received the long-awaited green- signal for releasing the version of Sanofi Aventis' anti-allergic drug, Allegra D-24. It is supposed to hit stores by first quarter 2011.

Bodhtree to help Dr Reddy's in application integration

Bodhtree to help Dr Reddy's in application integrationHyderabad, Dec 14 : IT services innovator Bodhtree Consulting Monday announced that Dr. Reddy's Laboratories has selected its data management and integration engine MIDAS (Multi Industry Data Anomaly Solution) to address its mission critical application integration challenges.

MIDAS will help Dr. Reddy's integrate mission critical applications and third party systems in a seamless manner, Bodhtree said in a statement here.

Dr. Reddy’s Laboratories Ltd Long Term Buy Call: Abhishek Jain, StocksIdea.com

 Abhishek Jain, StocksIdea.comCompany was incorporated on 2nd November 1985. Dr. K. Anji Reddy and his associates promoted company. Company established a subsidiary named "Dr. Reddy's Diagnostics Ltd." for the manufacture of diagnostics kits. Company also formed a joint venture "Reddy Biomed Ltd." with a Russian company for manufacturing and marketing formulation in Russia.

Pfizer Takes Legal Action Against Dr Reddy’s Over Lipitor

Pfizer Takes Legal Action Dr Reddy’s Over LipitorGlobal pharmaceutical major Pfizer has taken legal against Dr Reddy's Laboratories (DRL) over its anti-cholesterol medicine Lipitor, which is the world's largest selling drug having sales worth more than $8 billion.

Pfizer asked a judge to forbid sales of generic variants of 'Lipitor' until 2017.

Hyderabad-based Dr Reddy's has formulated Lipitor's generic variant, and has sought the USFDA's nod to sell copies of Lipitor in the market.

Dr Reddy's net profit surges 107%

Dr-Reddy-LaboratoriesDr Reddy's Laboratories, leading pharmaceutical company has clocked a substantial growth of 107% in its net profit which stood at Rs 217.3 crore for the second three month period ended September 2009.

During the similar period last year, company's net profit figure stood at Rs 105.2 crore.

Revenues of the company during the said quarter grew 13.72% to Rs 1,836.8 crore, as compared to Rs 1,615.1 crore in the similar quarter previous year.

Dr.Reddy's Lab net profit rises 116.52 percent

Dr.Reddy's Lab net profit rises 116.52 percentHyderabad, Oct 23 : Pharma major Dr. Reddy's Laboratories Friday said its net profit for the quarter ended Sep 30 grew 116.52 percent to Rs. 197 crore from Rs. 91 crore in the like quarter last fiscal.

Total income of the company increased 19.24 percent to Rs. 1,139 crore for the second quarter this fiscal from Rs. 955.18 crore in the corresponding period in 2008-09.

Dr. Reddy's logged a forex gain of Rs. 32.9 crore for the quarter ended Sep 30, compared to a forex loss of Rs. 47.2 crore in the like quarter a year ago.

Buy Dr Reddy To Achieve Short-Term Target Of Rs 910: Nirmal Bang

Buy Dr Reddy To Achieve Short-Term Target Of Rs 910: Nirmal BangIn its latest research report, Nirmal Bang, an equity research firm said that Dr Reddys Laboratories, which has been consolidating between Rs 820-833 level, can give good returns in the short term.

The report further stated that, if the counter is successful to breach Rs 870 levels, then it will create a huge breakout.

Nirmal Bang has advised investors that the stock of the company is giving an evidence of a strong breakout, so hold it to achieve a target price above Rs 910.

The stock has strong support at Rs 790.

Dr Reddy’s launches ‘Finrid’ in Indian Market

Fentanyl Transdem PatchDr. Reddy's Laboratories Ltd has finally launched Finrid (Fentanyl Transdem Patch) in domestic market.

The product is licensed from Sparsha pharma and is the first opiod (derived from Opium) transdermal patch to be developed in India

Finrid used in used in management of severe to moderate pain, as it provides continuous systemic delivery of Fentanyl, a potent opioid analgesic for upto 72 hours.

Dr Reddy's net surges 120%

Dr Reddy's signs pact with GSK Country's second-largest drug maker by sales, Dr Reddy's Laboratories (DRL) reported 120 per cent increase in its profit due to its efficient business management; new products launch and handling of cost issues without impacting its business.

Its net profit stood at Rs 244.5 crore for the first quarter ended June 30, 2009 as compared to Rs 111.1 crore in the same period last year. DRL reported 21 per cent rise in its income that stood at Rs 1,820 crore amid uncertain conditions of economic market.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content